Despite high serum levels of FST associating with poor prognosis in hepatocellular carcinoma [52, 53] and high tumour FST also representing a negative prognostic factor in lung, ovarian and gastric cancer [49], survival data from the TCGA database indicates that high tumoural expression of FST does not correlate with altered disease‐free survival of prostate cancer patients (Fig. S16). This evidence concerns the gene FST and prostate carcinoma.